Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

Risk of stroke and transient ischaemic attack after herpes zoster

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Circumcision and penile human papillomavirus prevalence in human immunodeficiency virus-infected men: heterosexual and men who have sex with men M.P.

Twelve years of dengue surveillance in Belgian travellers and significant increases in the number of cases in 2010 and 2013 J. Verschueren, L. Cnops,

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines.

Benchmarking inappropriate empirical antibiotic treatment

Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy S. Bertschy,

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Incidence and outcome of Staphylococcus aureus endocarditis—a 10-year single-centre northern European experience H. Asgeirsson, A. Thalme, M. Kristjansson,

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Association of CD209L tandem repeats polymorphism with susceptibility to human immunodeficiency virus-1 infection, disease progression, and treatment.

Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects K. Ekelund, P. Skinhøj, J. Madsen, H.B.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Candida glabrata fungaemia in intensive care units

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance—a retrospective population based study.

R. Cantón Clinical Microbiology and Infection

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

Clinical Microbiology and Infection

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain J.-M. Aguado, C. Lumbreras, D.

Vector control: a cornerstone in the malaria elimination campaign

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients

Sofie Arens, Jan Verhaegen, Ludo Verbist

Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia S.-C. Kuo, Y.-T. Lee,

Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy J. Cobo, L. Garcia San Miguel, G. Euba,

Retrospective study of CMV retinitis in patients with AIDS

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective.

Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit E. Theocharidou, B. Agarwal, G. Jeffrey,

Elements of design: the knowledge on which we build

Levofloxacin in the treatment of ventilator-associated pneumonia

J. Bodilsen, C. T. Brandt, A. Sharew, M. Dalager-Pedersen, T

Metagenomics and probiotics

Recent developments in staphylococcal scalded skin syndrome

J. Garau Clinical Microbiology and Infection

H. M. El Sahly, L.D. Teeter, J.M. Musser, E.A. Graviss

The role of antimalarial treatment in the elimination of malaria

Benchmarking inappropriate empirical antibiotic treatment

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial

Testing patients with non-specific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about.

Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection E. Knops, E. Heger Clinical Microbiology.

Current experience in treating invasive zygomycosis with posaconazole

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Gender differences in the outcome of community-acquired Staphylococcus aureus bacteraemia: a historical population-based cohort study J. Smit, L.E. López-Cortés,

Use of a multiplex real-time PCR to study the incidence of human metapneumovirus and human respiratory syncytial virus infections during two winter seasons.

Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective.

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Predictors of clinical and microbiological treatment failure in patients with methicillin- resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective.

Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis Z. Luo, Z. Fu, E. Liu, X. Xu, X. Fu, D. Peng,

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Control of human cytomegalovirus infection in patients infected with human immunodeficiency virus by high levels of specific CD8+ T-cells D. Lilleri,

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Serum ferritin levels in West Nile encephalitis

Modelling during an emergency: the 2009 H1N1 influenza pandemic

J.L. Balcázar Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies J.C. Martín, V Soriano,

Impact of antibiotic restrictions: the patient's perspective

Abstracts Clinical Microbiology and Infection

Localized Mycobacterium avium complex infection in a patient on HAART

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort C. Manzardo, A. Esteve, N. Ortega, D. Podzamczer, J. Murillas, F. Segura, L. Force, C. Tural, J. Vilaró, A. Masabeu, I. Garcia, M. Guadarrama, E. Ferrer, M. Riera, G. Navarro, B. Clotet, J.M. Gatell, J. Casabona, J.M. Miró Clinical Microbiology and Infection Volume 19, Issue 7, Pages 646-653 (July 2013) DOI: 10.1111/j.1469-0691.2012.03991.x Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Flow chart of exclusion from the study population. Of the 117 patients excluded because follow-up was <30 days, 35 were lost to follow-up and 82 presented with AIDS and/or died (43 presented with AIDS, 36 died and three presented with AIDS and died during the 30-day period). The 108 patients excluded because they did not meet the criteria for assignment to the early or late group were distributed as follows: three patients presented with AIDS or died during the late period (30–270 days) but started highly active antiretroviral therapy (HAART) after day 270; five patients presented with AIDS or died during days 270–365; 82 patients who did not present with an event during follow-up did not start HAART or started after day 270; and 18 patients started other antiretroviral treatments not classified as HAART. Clinical Microbiology and Infection 2013 19, 646-653DOI: (10.1111/j.1469-0691.2012.03991.x) Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Overall cumulative incidence of AIDS/death in antiretroviral-naïve patients presenting with an AIDS-defining disease (N = 625). p-Values after comparison between the early and deferred highly active antiretroviral therapy (HAART) groups: log-rank test. Clinical Microbiology and Infection 2013 19, 646-653DOI: (10.1111/j.1469-0691.2012.03991.x) Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions